Lung cancer screening--where we are in 2004 (take home messages).
The best prognosis for lung cancer can be expected by diagnosis at an early stage of the disease. Long-term survival may be improved by increasing the number of early-stage diagnoses. At the present time, three different screening tools for lung cancer are available: Low-dose CT scanning, sputum analysis and fluorescence bronchoscopy. Each of these tools has a different screening target. Low-dose CT scanning focusses on small pulmonary nodules, sputum analysis has the potential of detecting lung cancer of the central airways, and fluorescence bronchoscopy can identify pre-malignancy, carcinoma in situ and minimally invasive squamous cell carcinoma. The best way forward appears to be a combination of all techniques. Sputum analysis can be used to define a better-characterised risk population, and subsequently this population can undergo low-dose CT and fluorescence bronchoscopy.
Deppermann
Karl-Matthias
KM
Ruppiner Kliniken, Klinik für Pneumologie, D-16816 Neuruppin, Germany. k-m.deppermann@ruppiner-kliniken.de
D001999:Bronchoscopy / Q000379:methods; D005453:Fluorescence; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis*; D008403:Mass Screening / Q000379:methods*; D013183:Sputum / Q000166:cytology; D014057:Tomography, X-Ray Computed / Q000379:methods